Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

dc.contributor.authorYasin, Ayse Irem
dc.contributor.authorAydin, Sabin Goktas
dc.contributor.authorSumbul, Bilge
dc.contributor.authorKoral, Lokman
dc.contributor.authorSimsek, Melih
dc.contributor.authorGeredeli, Caglayan
dc.contributor.authorOzturk, Akin
dc.contributor.authorPerkin, Perihan
dc.contributor.authorDemirtas, Derya
dc.contributor.authorErdemoglu, Engin
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorCakir, Emre
dc.contributor.authorTanrikulu, Eda
dc.contributor.authorCoban, Ezgi
dc.contributor.authorOzcelik, Melike
dc.contributor.authorCelik, Sinemis
dc.contributor.authorTeker, Fatih
dc.contributor.authorAksoy, Asude
dc.contributor.authorFirat, Sedat T.
dc.contributor.authorTekin, Omer
dc.contributor.authorKalkan, Ziya
dc.contributor.authorTurken, Orhan
dc.contributor.authorOven, Bala B.
dc.contributor.authorDane, Faysal
dc.contributor.authorBilici, Ahmet
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorSeker, Mesut
dc.contributor.authorTurk, Haci M.
dc.contributor.authorGumus, Mahmut
dc.date.accessioned2023-02-21T12:42:05Z
dc.date.available2023-02-21T12:42:05Z
dc.date.issued2022-01-01
dc.description.abstractAim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2\% in the patient group and 97.5\% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: ClinicalTrials.gov) Plain language summary Cancer patients are at high risk for infection with SARS-CoV-2 and of developing the associated disease, COVID-19, which therefore puts them in the priority group for vaccination. This study evaluated the efficacy and safety of CoronaVac, an inactivated virus vaccine, in cancer patients. The immune response rate, defined as seropositivity, was 85.2\% in the cancer patient group and 97.5\% in the control group. The levels of antibodies, which are blood markers of immune response to the vaccine, were also significantly lower in the patient group, especially in those older than 60 years and receiving chemotherapy. These results highlight the importance of determining the effective vaccine type and dose in cancer patients to protect them from COVID-19 without disrupting their cancer treatment.
dc.description.issue10
dc.description.issueMAR
dc.description.pages1235-1244
dc.description.volume18
dc.identifier.doi10.2217/fon-2021-1248
dc.identifier.urihttps://hdl.handle.net/11443/2782
dc.identifier.urihttp://dx.doi.org/10.2217/fon-2021-1248
dc.identifier.wosWOS:000747186600001
dc.publisherFUTURE MEDICINE LTD
dc.relation.ispartofFUTURE ONCOLOGY
dc.subjectcancer
dc.subjectchemotherapy
dc.subjectCoronaVac
dc.subjectCOVID-19
dc.subjectCOVID-19 vaccines
dc.subjectimmunotherapy
dc.subjectmalignancy
dc.subjectSARS-CoV-2
dc.titleEfficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
fon-2021-1248.pdf
Size:
1.37 MB
Format:
Adobe Portable Document Format

Collections